These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 18816678)
1. What is the role and significance of serum and stool biomarkers in the diagnosis of IBD? Palmon R; Brown SJ; Abreu MT Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S187-9. PubMed ID: 18816678 [TBL] [Abstract][Full Text] [Related]
2. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Kopylov U; Rosenfeld G; Bressler B; Seidman E Inflamm Bowel Dis; 2014 Apr; 20(4):742-56. PubMed ID: 24562174 [TBL] [Abstract][Full Text] [Related]
3. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Mosli MH; Zou G; Garg SK; Feagan SG; MacDonald JK; Chande N; Sandborn WJ; Feagan BG Am J Gastroenterol; 2015 Jun; 110(6):802-19; quiz 820. PubMed ID: 25964225 [TBL] [Abstract][Full Text] [Related]
4. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932 [No Abstract] [Full Text] [Related]
11. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. Abej E; El-Matary W; Singh H; Bernstein CN Can J Gastroenterol Hepatol; 2016; 2016():2483261. PubMed ID: 27774443 [No Abstract] [Full Text] [Related]
12. Disease monitoring in inflammatory bowel disease. Chang S; Malter L; Hudesman D World J Gastroenterol; 2015 Oct; 21(40):11246-59. PubMed ID: 26523100 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH; Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483 [TBL] [Abstract][Full Text] [Related]
14. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing]. Lasson A Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2645-9. PubMed ID: 21137533 [No Abstract] [Full Text] [Related]
15. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]
16. Fecal biomarkers in inflammatory bowel disease: how, when and why? Ministro P; Martins D Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):317-328. PubMed ID: 28276813 [TBL] [Abstract][Full Text] [Related]
17. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259 [TBL] [Abstract][Full Text] [Related]
18. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. Sydora MJ; Sydora BC; Fedorak RN J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175 [TBL] [Abstract][Full Text] [Related]
19. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use. Subramanian S; Asher R; Weston W; Rimmer M; McConville A; Malin A; Jackson R; Collins P; Probert C; Dibb M; Rhodes JM Inflamm Bowel Dis; 2016 Aug; 22(8):1902-7. PubMed ID: 27243590 [TBL] [Abstract][Full Text] [Related]
20. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]